The global neuroscience research landscape is undergoing significant transformation as biotechnology company Creative Biolabs unveils a comprehensive suite of advanced platforms designed to accelerate brain research. This development comes at a critical time when neurodegenerative diseases, particularly Alzheimer's, are affecting millions worldwide. The World Health Organization reports more than 55 million people currently live with dementia globally, with Alzheimer's disease accounting for up to 70% of dementia cases.
Creative Biolabs has addressed the growing demand for translational neuroscience tools by developing specialized platforms focusing on key cellular mechanisms in both peripheral and central nervous systems. For peripheral nervous system research, the company launched a complete Schwann Cell Assay platform capable of isolating Schwann cells from three species: human, mouse, and rat. This platform supports a co-culture system using neurons, enabling scientists to assess critical functional measures including neurotrophic factor secretion and myelination potential, both fundamental to regenerative medicine advancements.
Within the central nervous system, Creative Biolabs introduced its microglia phagocytosis assay service, utilizing live-cell imaging and fluorescently labelled bioparticles. This technology allows researchers to visualize microglial phagocytic function in real time, providing crucial insights into how the brain's resident immune cells manage neural homeostasis and respond to neuroinflammation while eliminating pathological protein aggregates.
The company has also developed comprehensive preclinical and research assessment services for Alzheimer's disease models, featuring both 2D and 3D platforms that represent key disease aspects including amyloid deposition, tauopathy, and neuroinflammation. These models can replicate both familial and sporadic forms of Alzheimer's disease, initiated from patient-derived induced pluripotent stem cells, creating a more rigorous context for drug screening and mechanistic studies.
An upcoming webinar scheduled for September 18, 2025, will further explore the role of microglia in Alzheimer's disease, providing additional educational opportunities for researchers in this field. The development of these advanced platforms represents a significant step forward in neuroscience research capabilities, potentially accelerating the pace of discovery and therapeutic development for neurodegenerative conditions that affect millions worldwide.
